LIVERPOOL (MedPage Today) -- Patients with rheumatoid arthritis who have interstitial lung disease (ILD) appeared to have a survival advantage if treated with rituximab rather than with a tumor necrosis factor (TNF) inhibitor, a researcher said here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment